Most patients with SCLC only survive 1 year or less after diagnosis [3]. The active exploration of the pathogenesis of lung cancer indicates that the identification of new biomarkers related to this disease may be crucial for the treatment and prognosis of patients with this malignancy [4, 5...
Lung cancer is the leading cause of cancer death worldwide, and about one half of patients with lung cancer are active smokers at diagnosis. Objective: To determine whether quitting smoking after diagnosis of lung cancer affects the risk for disease progression and mortality. Design: Prospective st...
Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer nucleic acids (i.e., DNA and microRNAs) have the potential to become suitable blood-based markers for diagnosis and progression of lung cancer. The......
Aberrant activation of epidermal growth factor receptor (EGFR) signaling is closely related to the development of non-small cell lung cancer (NSCLC). However, targeted EGFR therapeutics such as tyrosine kinase inhibitors (TKIs) face the challenge of EGFR mutation-mediated resistance. Here, we showed...
Aberrant fucosylation observed in cancer cells contributes to an augmented release of fucosylated exosomes into the bloodstream, where miRNAs including miR-4732-3p hold promise as potential tumor biomarkers in our pilot study. However, the mechanisms und
Table 3 The potential role of exo-circRNAs as biomarkers in the diagnosis and treatment of lung cancer Full size table In contrast to the above, several circRNAs act as tumor suppressors, and they inhibit lung cancer cell proliferation. For example, the expression level of circ_0006677 was lowe...
www.nature.com/scientificreports OPEN Elucidating Genomic Characteristics of Lung Cancer Progression from In Situ to Invasive Adenocarcinoma received: 14 May 2016 accepted: 19 July 2016 Published: 22 August 2016 Chanida Vinayanuwattikun1,2, Florence Le Calvez-Kelm1, Behnoush Abedi- Ardekani1,...
Using a modified Delphi process, we surveyed a group of lung cancer experts about tumor growth, disease progression, and prognosis in patients with malignant SPN. After completing the first survey, experts were given the opportunity during a second survey to revise their responses in light of thei...
FBXO32, a member of the F-box protein family, is known to play both oncogenic and tumor-suppressive roles in different cancers. However, the functions and the molecular mechanisms regulated by FBXO32 in lung adenocarcinoma (LUAD) remain unclear. Here, we
Significantly high-expressed circFLNA has been found in various cancer cell lines, but not in lung cancer. Therefore, this study aimed to explore the role of circFLNA in the progression of lung cancer. The target gene of circFLNA was determined by bioinf